Fluzone High-Dose vaccine — Competitive Intelligence Brief

Fluzone High-Dose vaccine (Fluzone High-Dose vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology.

marketed inactivated influenza vaccine Immunology Biologic

Target snapshot

Fluzone High-Dose vaccine (Fluzone High-Dose vaccine) — Sanofi Pasteur, a Sanofi Company. Fluzone High-Dose vaccine stimulates a stronger immune response against influenza virus strains by delivering four times the standard antigen dose per strain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluzone High-Dose vaccine TARGET	Fluzone High-Dose vaccine	Sanofi Pasteur, a Sanofi Company	marketed	inactivated influenza vaccine
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine
Vaxigrip®	Vaxigrip®	National University Hospital, Singapore	marketed	Inactivated influenza vaccine
Seasonal trivalent vaccine	Seasonal trivalent vaccine	Sinovac Biotech Co., Ltd	marketed	Inactivated influenza vaccine
trivalent seasonal influenza vaccine	trivalent seasonal influenza vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Standard IIV4	Standard IIV4	Marshfield Clinic Research Foundation	marketed	Inactivated influenza vaccine
Trivalent sub-unit influenza vaccine	Trivalent sub-unit influenza vaccine	University of Witwatersrand, South Africa	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

1. Seqirus · 3 drugs in this class
2. Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
4. Sinovac Biotech Co., Ltd · 2 drugs in this class
5. La Jolla Institute for Immunology · 1 drug in this class
6. Mount Sinai Hospital, Canada · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. GlaxoSmithKline · 1 drug in this class
10. University of Witwatersrand, South Africa · 1 drug in this class